11.12.2009 • News

Bartec Takes Over Vodec

Bartec, one of the internationally leading providers of industrial safety technology headquartered in Bad Mergentheim, Germany, has taken over Vodec, a British provider of communication and security systems. This acquisition is another milestone within the growth strategy of the internationally operating group of companies whose products and services are applied in all areas where hazardous substances such as combustible liquids, gases and dusts occur.
Vodec company, which is located in Nottingham, is specialized in the production of communication and security systems applied in areas where explosive atmospheres may occur. These communication solutions are used, for instance, on an oil rig or in a chemical plant in order to warn the employees on site of any possible dangers. The new business unit is an ideal complement to the Bartec product portfolio which does not only comprise explosion-proof components and system solutions but also heating technology, measurement and analysis technology as well as products used in the mining industry.
Bartec will run Vodec as a self-dependent company within the Bartec Group and the new business unit which will operate under the name of Bartec Vodec will be continuously expanded. The products and solutions will be marketed via the international Bartec sales network comprising 26 sales units as well as more than 50 representatives.
"Due to the integration of the communication and security system provider Vodec the product portfolio of the Bartec Group as well as our know-how in providing solutions will be further strengthened," said
 Dr. Ralf Köster, CEO of the Bartec Group.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read